Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 3/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 2/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 2/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | PRKCG | P05129 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-220025 SCHEMBL18066291 | 0.99 | MAPK14 (0.98) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL1906575 | 0.94 | MAPK14 (0.88) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL20550753 | 0.93 | MAPK14 (0.91) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL20550893 | 0.90 | MAPK14 (0.98) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL20550876 | 0.90 | MAPK14 (0.93) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL29842083 | 0.90 | MAPK14 (0.98) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL4585589 | 0.89 | MAPK14 (0.80) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL1640467 | 0.89 | MAPK14 (0.80) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL20550488 | 0.89 | MAPK14 (1.00) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL1640842 | 0.89 | MAPK14 (0.80) | MAPK14CSNK1DMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 495 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | claimed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | claimed |
| US-20210186943-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2021-06-24 | — | — | US | claimed |
| EP-3810146-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | Otonomy, Inc. (US) | 2021-04-28 | — | — | EP | claimed |
| US-20200237728-A1 | CHEMOTHERAPEUTIC METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2020-07-30 | — | — | US | claimed |
| EP-3111937-B1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2020-06-17 | — | — | EP | claimed |
| EP-3501521-A1 | PREVENTION OF AND RECOVERY FROM DRUG-INDUCED OTOTOXICITY | Otonomy, Inc. (US) | 2019-06-26 | — | — | EP | claimed |
| US-20180036231-A1 | PREVENTION OF AND RECOVERY FROM DRUG-INDUCED OTOTOXICITY | OTONOMY, INC. | 2018-02-08 | — | — | US | claimed |
| WO-2012112810-A1 | PREVENTION OF AND RECOVERY FROM DRUG-INDUCED OTOTOXICITY | OTONOMY, INC. (US) | 2012-08-23 | — | — | WO | claimed |
| US-7662389-B2 | Gene expression inhibition; p38 map kinase inhibitors | ALCON, INC. (CH) | 2010-02-16 | — | — | US | claimed |
| EP-1196167-B1 | Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions | LIPTON STUART A (US) | 2006-04-19 | — | — | EP | claimed |
| EP-1542768-A1 | USE OF CYTOKINE SYNTHESIS INHIBITORS FOR THE TREATMENT OF DRY EYE DISORDERS | Alcon, Inc. (CH) | 2005-06-22 | — | — | EP | claimed |
| WO-2004026406-A1 | USE OF CYTOKINE SYNTHESIS INHIBITORS FOR THE TREATMENT OF DRY EYE DISORDERS | ALCON, INC. (CH) | 2004-04-01 | — | — | WO | claimed |
| US-20040058875-A1 | Methods of treating dry eye disorders | ALCON, INC. | 2004-03-25 | — | — | US | claimed |
| US-20030078274-A1 | Method of reducing neuronal injury or apoptosis | LIPTON STUART A (US) | 2003-04-24 | — | — | US | claimed |
| EP-0708768-B1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | claimed |
| CN-1050126-C | Tri-substituted imidazoles, their preparation and use and pharmaceutical compositions containing them | SMITHKLINE BEECHAM CORP (US) | 2000-03-08 | — | — | CN | claimed |
| CN-1129447-A | Trisubstituted imidazoles having multiple therapeutic effects | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186943-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | TRPV1, TRPV2, TRPA1 | MAPK14 91/4885CSNK1D 2242/4885MAPK13 107/4885 |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885CSNK1D 2750/4885MAPK13 23/4885 |
| US-20180036231-A1 | PREVENTION OF AND RECOVERY FROM DRUG-INDUCED OTOTOXICITY | OTC, SLC26A4, ALDH1A3 | MAPK14 3792/4885CSNK1D 4777/4885MAPK13 3750/4885 |
| US-20030078274-A1 | Method of reducing neuronal injury or apoptosis | GAP43, DCX, NLN | MAPK14 40/4885CSNK1D 3571/4885MAPK13 129/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | MAPK14 14/4885CSNK1D 2750/4885MAPK13 23/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885CSNK1D 2836/4885MAPK13 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.